Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

As the close run­ner-up to Am­gen’s Lumakras in the KRAS race, any da­ta cut from Mi­rati’s ada­gra­sib con­tin­ues to draw scruti­ny from an­a­lysts. And the lat­est batch of num­bers from AS­CO is a de­cid­ed­ly mixed bag.

While a quick com­par­i­son sug­gests that ada­gra­sib spurred slight­ly more re­spons­es and led to a longer over­all sur­vival than Lumakras among a group of non-small cell lung can­cer pa­tients, its du­ra­tion of re­sponse ap­pears short­er and the safe­ty pro­file con­tin­ues to spark con­cern.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER